O-235 Accommodating prior beliefs in the analysis of phase III clinical trials: A bayesian view on results from trials of chemotherapy in non-small cell lung cancer

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S69
Author(s):  
Lucinda J. Billingham ◽  
Michael Cullen
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Prior Beliefs ◽  
Phase Iii Clinical Trials

scholarly journals Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride

2011 ◽  
Vol 5 ◽  
pp. CMO.S5072 ◽  
Author(s):  
Tatsuo Kimura ◽  
Shinzoh Kudoh ◽  
Kazuto Hirata
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Regression ◽  
Small Cell ◽  
Phase Iii ◽  
In Vivo Studies ◽  
Small Cell Lung

Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. Here, we discuss the features of SCLC, the chemistry, pharmacokinetics, and pharmacodynamics of AMR, the results of in vitro and in vivo studies, and the efficacy and safety of AMR monotherapy and combination therapy in clinical trials. With its predictable and manageable toxicities, AMR is one of the most attractive agents for the treatment of chemotherapy-sensitive and -refractory relapsed SCLC. Numerous studies are ongoing to define the applicability of AMR therapy for patients with SCLC. These clinical trials, including phase III studies, will clarify the status of AMR in the treatment of SCLC.

Necitumumab for the treatment of squamous cell non-small cell lung cancer

2016 ◽  
Vol 24 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Jessica K Brinkmeyer ◽  
Donald C Moore
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Small Cell Lung Cancer ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Effective Treatment Option ◽  
Two Phase

Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all cases and is further subdivided into adenocarcinoma, squamous cell, and large cell carcinoma. Necitumumab (Portrazza™, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell non-small cell lung cancer in combination with cisplatin and gemcitabine. The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer. Necitumumab is associated with adverse events such as infusion reactions, hypomagnesemia, diarrhea, and dermatological toxicities. Although considered a safe and effective treatment option for squamous cell non-small cell lung cancer, the clinical utility of necitumumab may be limited due to the high cost of the drug as well as added toxicity when combined with cisplatin and gemcitabine. Several clinical trials are ongoing in order to further investigate the utilization of necitumumab.

scholarly journals Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer

2016 ◽  
Vol 5 (9) ◽  
pp. 2190-2197 ◽  
Author(s):  
Cristina Fernández‐López ◽  
José Expósito‐Hernández ◽  
Juan Pedro Arrebola‐Moreno ◽  
Miguel Ángel Calleja‐Hernández ◽  
Manuela Expósito‐Ruíz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Controlled Clinical Trials ◽  
Small Cell Lung ◽  
Randomized Controlled Clinical Trials ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document